5-Amino-1MQ (2 x 10mg vials)

5-Amino-1MQ

5-Amino-1MQ, also written as 5-amino-1-methylquinolinium, is a small-molecule nicotinamide N-methyltransferase (NNMT) inhibitor used in metabolic research. Available draft box combinations are 20mg, 50mg, and 100mg, built from 10mg vials.

Peptide Partners Manufacturer ID: WF03

Batch ID: AM202604

CAS: 42464-96-0

Molecular Formula: C10H11IN2

Research Studies

(for educational purposes only)

Selective and Membrane-Permeable Small Molecule Inhibitors of Nicotinamide N-Methyltransferase Reverse High Fat Diet-Induced Obesity in Mice

Authors: Harshini Neelakantan, Virginia Vance, Michael D. Wetzel, Hua-Yu Leo Wang, Stanton F. McHardy, Celeste C. Finnerty, Jonathan D. Hommel, Stanley J. Watowich

Published: Biochemical Pharmacology, 2018 Jan;147:141-152

URL: https://pubmed.ncbi.nlm.nih.gov/29155147/

This preclinical study evaluated methylquinolinium-based inhibitors of nicotinamide N-methyltransferase (NNMT), including 5-amino-1-methylquinolinium. The researchers reported that 5-Amino-1MQ showed high membrane permeability and selectivity for NNMT without inhibiting structurally related SAM-dependent methyltransferases or enzymes in the NAD+ salvage pathway. In cultured adipocytes, NNMT inhibition reduced intracellular 1-methylnicotinamide, increased NAD+ and SAM, and suppressed lipogenesis. In diet-induced obese mice, systemic treatment with an NNMT inhibitor significantly reduced body weight, white adipose tissue mass, adipocyte size, and plasma total cholesterol without changing total food intake or producing observable adverse effects in the study window.

In plain English

This is the core animal/mechanism paper for 5-Amino-1MQ. The compound was studied as an NNMT inhibitor — not as an appetite suppressant. In cells and mice, blocking NNMT shifted metabolic chemistry in a way that increased NAD+ and SAM availability and reduced fat-building signals. The mouse data are promising, but they are preclinical and do not establish human outcomes.

Reduced Calorie Diet Combined With NNMT Inhibition Establishes a Distinct Microbiome in DIO Mice

Authors: Andrea Dimet-Wiley, Qinglong Wu, Jerrin T. Wiley, Aditya Eswar, Harshini Neelakantan, Tor Savidge, Stanley J. Watowich

Published: Scientific Reports, 2022;12:358

URL: https://pubmed.ncbi.nlm.nih.gov/35013352/

This study examined diet-induced obese mice treated with a nicotinamide N-methyltransferase inhibitor, identified as 5-amino-1-methylquinolinium, while switching from a Western/high-fat diet to a low-fat diet. The NNMT inhibitor plus diet switch produced a distinct cecal microbiome profile compared with diet switch alone. Reported changes included increased Lactobacillus and decreased Erysipelatoclostridium, with microbiome patterns correlating with rapid normalization of body weight and adiposity measures toward lean-control levels. The study used 16S rRNA sequencing and adipose-tissue metabolite correlation analyses to evaluate treatment-associated microbial and metabolic shifts.

In plain English

This mouse study looked beyond weight change and asked whether NNMT inhibition changes the gut microbiome during diet-driven weight loss. The researchers found that adding the NNMT inhibitor produced a different microbial signature than diet change alone. It supports the idea that NNMT inhibition may interact with broader metabolic systems, but it remains animal research.

Roles of Nicotinamide N-Methyltransferase in Obesity and Type 2 Diabetes

Authors: Jie-Ru Liu, Zhao-Hui Deng, Xiao-Juan Zhu, Yu-Rong Zeng, Xiang-Xiang Guan, Jiang-Hua Li

Published: BioMed Research International, 2021

URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC8337113/

This review summarizes evidence linking NNMT activity with obesity and type 2 diabetes biology. NNMT methylates nicotinamide using S-adenosylmethionine, which can alter NAD+ salvage chemistry, methyl-donor balance, and downstream energy-metabolism pathways. The review discusses 5-Amino-1MQ as a membrane-permeable NNMT inhibitor that reduced intracellular 1-methylnicotinamide, increased NAD+, suppressed lipogenesis, and reduced body weight in preclinical models. It also notes that NNMT knockdown or inhibition has been associated with increased energy expenditure, reduced fat mass, and improved insulin-sensitivity markers in animal and cellular studies.

In plain English

This paper is a broader review of the target that 5-Amino-1MQ acts on. NNMT is involved in how cells handle nicotinamide, NAD+, methyl groups, fat storage, and glucose metabolism. The review places 5-Amino-1MQ inside that larger NNMT research landscape and makes clear that the strongest evidence is still preclinical.

Related Products

• GLP-1 Semaglutide (20 x 10mg vials)
• GLP-1 Semaglutide (15 x 10mg vials)
• GLP-1 Semaglutide (10 x 10mg vials)

Browse more in Metabolics.